Shanghai RAAS Blood Products Co Ltd Class A (002252) - Net Assets

Latest as of March 2026: CN¥32.52 Billion CNY ≈ $4.76 Billion USD

Based on the latest financial reports, Shanghai RAAS Blood Products Co Ltd Class A (002252) has net assets worth CN¥32.52 Billion CNY (≈ $4.76 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥37.98 Billion ≈ $5.56 Billion USD) and total liabilities (CN¥5.46 Billion ≈ $798.84 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shanghai RAAS Blood Products Co Ltd Clas tangible equity quality to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥32.52 Billion
% of Total Assets	85.63%
Annual Growth Rate	28.03%
5-Year Change	25.34%
10-Year Change	176.78%
Growth Volatility	162.28

Shanghai RAAS Blood Products Co Ltd Class A - Net Assets Trend (2005–2025)

This chart illustrates how Shanghai RAAS Blood Products Co Ltd Class A's net assets have evolved over time, based on quarterly financial data. See 002252 days of operational coverage to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)

The table below shows the annual net assets of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2025. For live valuation and market cap data, see market cap of Shanghai RAAS Blood Products Co Ltd Clas.

Year	Net Assets	Change
2025-12-31	CN¥32.47 Billion ≈ $4.75 Billion	+1.65%
2024-12-31	CN¥31.94 Billion ≈ $4.67 Billion	+7.73%
2023-12-31	CN¥29.65 Billion ≈ $4.34 Billion	+2.90%
2022-12-31	CN¥28.81 Billion ≈ $4.22 Billion	+11.23%
2021-12-31	CN¥25.90 Billion ≈ $3.79 Billion	+3.08%
2020-12-31	CN¥25.13 Billion ≈ $3.68 Billion	+118.69%
2019-12-31	CN¥11.49 Billion ≈ $1.68 Billion	+5.42%
2018-12-31	CN¥10.90 Billion ≈ $1.60 Billion	-12.66%
2017-12-31	CN¥12.48 Billion ≈ $1.83 Billion	+6.39%
2016-12-31	CN¥11.73 Billion ≈ $1.72 Billion	+9.50%
2015-12-31	CN¥10.71 Billion ≈ $1.57 Billion	+24.21%
2014-12-31	CN¥8.62 Billion ≈ $1.26 Billion	+682.76%
2013-12-31	CN¥1.10 Billion ≈ $161.22 Million	+8.07%
2012-12-31	CN¥1.02 Billion ≈ $149.18 Million	+9.94%
2011-12-31	CN¥927.27 Million ≈ $135.69 Million	+11.56%
2010-12-31	CN¥831.21 Million ≈ $121.63 Million	+8.89%
2009-12-31	CN¥763.33 Million ≈ $111.70 Million	+1.14%
2008-12-31	CN¥754.76 Million ≈ $110.45 Million	+343.95%
2007-12-31	CN¥170.01 Million ≈ $24.88 Million	+8.44%
2006-12-31	CN¥156.77 Million ≈ $22.94 Million	-32.34%
2005-12-31	CN¥231.70 Million ≈ $33.90 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Shanghai RAAS Blood Products Co Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 7762.9% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥11.02 Billion	33.96%
Common Stock	CN¥6.64 Billion	20.45%
Other Comprehensive Income	CN¥1.12 Billion	3.45%
Other Components	CN¥13.68 Billion	42.14%
Total Equity	CN¥32.46 Billion	100.00%

Shanghai RAAS Blood Products Co Ltd Class A Competitors by Market Cap

The table below lists competitors of Shanghai RAAS Blood Products Co Ltd Class A ranked by their market capitalization.

Company	Market Cap
Vita Coco Company Inc NASDAQ:COCO	$4.49 Billion
Wuhan Raycus Fiber Laser Technologies Co Ltd Class A SHE:300747	$4.49 Billion
Koninklijke Vopak NV AS:VPK	$4.49 Billion
Cavco Industries Inc NASDAQ:CVCO	$4.50 Billion
Indian Railway Catering And Tourism Corporation Limited NSE:IRCTC	$4.49 Billion
TaTaTu SpA PA:ALTTU	$4.48 Billion
BILFINGER SE UNSP.ADR 1/5 F:GBFU	$4.48 Billion
JHT Design Co. Ltd. Cl A SHG:603061	$4.48 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shanghai RAAS Blood Products Co Ltd Class A's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 31,926,258,696 to 32,456,025,360, a change of 529,766,664 (1.7%).
Net income of 1,577,013,865 contributed positively to equity growth.
Dividend payments of 317,875,597 reduced retained earnings.
Share repurchases of 478,007,824 reduced equity.
Other comprehensive income increased equity by 1,119,909,967.
Other factors decreased equity by 1,371,273,747.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥1.58 Billion	+4.86%
Dividends Paid	CN¥317.88 Million	-0.98%
Share Repurchases	CN¥478.01 Million	-1.47%
Other Comprehensive Income	CN¥1.12 Billion	+3.45%
Other Changes	CN¥-1.37 Billion	-4.23%
Total Change	CN¥-	1.66%

Book Value vs Market Value Analysis

This analysis compares Shanghai RAAS Blood Products Co Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.94x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 19.10x to 0.94x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2005-12-31	CN¥0.24	CN¥4.62	x
2006-12-31	CN¥0.16	CN¥4.62	x
2007-12-31	CN¥0.06	CN¥4.62	x
2008-12-31	CN¥0.24	CN¥4.62	x
2009-12-31	CN¥0.22	CN¥4.62	x
2010-12-31	CN¥0.23	CN¥4.62	x
2011-12-31	CN¥0.26	CN¥4.62	x
2012-12-31	CN¥0.28	CN¥4.62	x
2013-12-31	CN¥0.29	CN¥4.62	x
2014-12-31	CN¥2.06	CN¥4.62	x
2015-12-31	CN¥2.15	CN¥4.62	x
2016-12-31	CN¥2.40	CN¥4.62	x
2017-12-31	CN¥2.53	CN¥4.62	x
2018-12-31	CN¥2.22	CN¥4.62	x
2019-12-31	CN¥2.27	CN¥4.62	x
2020-12-31	CN¥3.73	CN¥4.62	x
2021-12-31	CN¥3.84	CN¥4.62	x
2022-12-31	CN¥4.28	CN¥4.62	x
2023-12-31	CN¥4.50	CN¥4.62	x
2024-12-31	CN¥4.80	CN¥4.62	x
2025-12-31	CN¥4.94	CN¥4.62	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shanghai RAAS Blood Products Co Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 4.86%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 21.46%
• Asset Turnover: 0.19x
• Equity Multiplier: 1.16x
Recent ROE (4.86%) is below the historical average (13.38%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2005	22.14%	16.90%	0.91x	1.44x	CN¥28.10 Million
2006	32.41%	18.20%	0.86x	2.08x	CN¥35.06 Million
2007	48.66%	26.38%	1.01x	1.82x	CN¥64.96 Million
2008	13.95%	33.82%	0.37x	1.11x	CN¥29.67 Million
2009	17.88%	35.01%	0.47x	1.09x	CN¥59.81 Million
2010	22.51%	38.38%	0.52x	1.13x	CN¥103.09 Million
2011	21.91%	35.31%	0.56x	1.10x	CN¥108.89 Million
2012	22.42%	33.96%	0.55x	1.20x	CN¥124.65 Million
2013	13.23%	28.97%	0.32x	1.45x	CN¥35.07 Million
2014	5.93%	38.71%	0.14x	1.09x	CN¥-350.12 Million
2015	13.53%	71.64%	0.17x	1.08x	CN¥376.57 Million
2016	13.78%	69.35%	0.18x	1.13x	CN¥442.28 Million
2017	6.71%	43.36%	0.13x	1.16x	CN¥-410.35 Million
2018	-13.95%	-84.16%	0.16x	1.05x	CN¥-2.61 Billion
2019	5.30%	23.52%	0.22x	1.03x	CN¥-539.98 Million
2020	5.27%	47.93%	0.11x	1.01x	CN¥-1.19 Billion
2021	5.00%	30.19%	0.16x	1.05x	CN¥-1.30 Billion
2022	6.52%	28.63%	0.22x	1.06x	CN¥-1.00 Billion
2023	6.00%	22.34%	0.25x	1.08x	CN¥-1.18 Billion
2024	6.87%	26.82%	0.24x	1.05x	CN¥-999.33 Million
2025	4.86%	21.46%	0.19x	1.16x	CN¥-1.67 Billion

Industry Comparison

This section compares Shanghai RAAS Blood Products Co Ltd Class A's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $1,059,329,361
Average return on equity (ROE) among peers: 7.95%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Shanghai RAAS Blood Products Co Ltd Class A (002252)	CN¥32.52 Billion	22.14%	0.17x	$4.49 Billion
Shenzhen CAU Technology Co Ltd (000004)	$124.02 Million	4.50%	1.13x	$6.01 Million
Pacific Shuanglin Bio pharmacy Co Ltd (000403)	$687.82 Million	11.47%	1.00x	$1.36 Billion
Nanhua Bio Medicine Co Ltd (000504)	$443.86 Million	6.71%	0.36x	$397.93 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518)	$1.11 Billion	1.01%	0.26x	$503.19 Million
Chengzhi Shareholding Co Ltd (000990)	$975.70 Million	5.10%	0.96x	$1.57 Billion
Hualan Biological EngineeringInc (002007)	$2.58 Billion	14.36%	0.06x	$3.46 Billion
Da An Gene Co Ltd of Sun Yat-Sen University (002030)	$385.31 Million	9.07%	0.38x	$1.12 Billion
Baolingbao Biology Co Ltd (002286)	$1.48 Billion	2.77%	0.29x	$506.21 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287)	$1.75 Billion	16.55%	0.19x	$1.66 Billion

About Shanghai RAAS Blood Products Co Ltd Class A

SHE:002252 China Biotechnology

Market Cap

$4.49 Billion

CN¥30.67 Billion CNY

Market Cap Rank

#3871 Global

#599 in China

Share Price

CN¥4.62

Change (1 day)

+0.87%

52-Week Range

CN¥4.58 - CN¥7.18

All Time High

CN¥24.72